

## DAFTAR PUSTAKA

- ADA (2023) *How COVID-19 Impacts People with Diabetes*, American Diabetes Association. Available at: <https://diabetes.org/coronavirus-covid-19/how-coronavirus-impacts-people-with-diabetes> (Accessed: 5 May 2023).
- Alexaki, V.I. and Henneicke, H. (2021) ‘The Role of Glucocorticoids in The Management of COVID-19’, *Hormone and Metabolic Research*, 53(1), pp. 9–15. Available at: <https://doi.org/10.1055/a-1300-2550>.
- Andra Farm (2022) *Sebaran Virus Corona di Kota Jakarta Selatan*. Available at: [https://m.andrafarm.com/\\_andra.php?\\_i=daftar-co19-kota&idprovget=6&no neg=42-6&perhal=50&asc=01101001000&urut=4&grafik=4#posisigrafikc](https://m.andrafarm.com/_andra.php?_i=daftar-co19-kota&idprovget=6&no neg=42-6&perhal=50&asc=01101001000&urut=4&grafik=4#posisigrafikc) (Accessed: 14 September 2022).
- Bergmann, C.C. and Silverman, R.H. (2020) ‘COVID-19: Coronavirus Replication, Rathogenesis, and Therapeutic Strategies’, *Cleveland Clinic Journal of Medicine*, 87(5), pp. 321–327. Available at: <https://doi.org/10.3949/CCJM.87A.20047>.
- Bramante, C.T. *et al.* (2021) ‘Metformin and Risk of Mortality in Patients Hospitalised with COVID-19: a Retrospective Cohort Analysis’, *Lancet Healthy Longev*, 2(1), pp. e34–e41. Available at: [https://doi.org/10.1016/S2666-7568\(20\)30033-7](https://doi.org/10.1016/S2666-7568(20)30033-7).
- Burhan, E *et al.* (2022) *Pedoman Tatalaksana COVID-19*. 4th edn. Edited by Erlina Burhan *et al.*
- Bwire, G.M. (2020) ‘Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women?’, *SN Comprehensive Clinical Medicine*, 2(7), pp. 874–876. Available at: <https://doi.org/10.1007/s42399-020-00341-w>/Published.
- Carfora, V. *et al.* (2021) ‘Anticoagulant Treatment in COVID-19: a Narrative Review’, *Journal of Thrombosis and Thrombolysis*, 51(3), pp. 642–648. Available at: <https://doi.org/10.1007/s11239-020-02242-0>.
- Carty, M., Guy, C. and Bowie, A.G. (2021) ‘Detection of Viral Infections by Innate Immunity’, *Biochemical Pharmacology*. Elsevier Inc. Available at: <https://doi.org/10.1016/j.bcp.2020.114316>.

- Cascella, M. *et al.* (2022) *Features, Evaluation, and Treatment of Coronavirus (COVID-19)*, Statpearl Publishing. Statpearl Publishing.
- CDC (2021) *Basics of COVID-19*. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/your-health/about-covid-19/basics-covid-19.html> (Accessed: 7 August 2022).
- El Chakhtoura, N.G., Bonomo, R.A. and Jump, R.L.P. (2017) 'Influence of Aging and Environment on Presentation of Infection in Older Adults', *Infectious Disease Clinics of North America*, 31(4), pp. 593–608. Available at: <https://doi.org/10.1016/j.idc.2017.07.017>.
- Chee, Y.J., Tan, S.K. and Yeoh, E. (2020) 'Dissecting The Interaction between COVID-19 and Diabetes Mellitus', *Journal of Diabetes Investigation*. Blackwell Publishing, pp. 1104–1114. Available at: <https://doi.org/10.1111/jdi.13326>.
- Chen, Y. *et al.* (2020) 'Clinical Characteristics and Outcomes of Patients with Diabetes and COVID-19 in Association with Glucose-Lowering Medication', *Diabetes Care*, 43(7), pp. 1399–1407. Available at: <https://doi.org/10.2337/dc20-0660>.
- Chen, Y. *et al.* (2022) 'The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis', *Frontiers in Endocrinology*. Frontiers Media S.A. Available at: <https://doi.org/10.3389/fendo.2022.895458>.
- Cheng, X. *et al.* (2020) 'Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-Existing Type 2 Diabetes', *Cell Metabolism*, 32(4), pp. 537–547. Available at: <https://doi.org/10.1016/j.cmet.2020.08.013>.
- Corcoran, C. and Jacobs, T.F. (2022) 'Metformin', *StatPearls Publishing*, 1. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK518983/>.
- Daiber, A. *et al.* (2019) 'New Therapeutic Implications of Endothelial Nitric Oxide Synthase (eNOS) Function/Dysfunction in Cardiovascular Disease', *International Journal of Molecular Sciences*, 20(1). Available at: <https://doi.org/10.3390/ijms20010187>.

- Dhatariya, K., Corsino, L. and Umpierrez, G.E. (2020) *Management of Diabetes and Hyperglycemia in Hospitalized Patients*. Edited by F. KR et al. Endotext.
- Fernandez, D.R. and Crow, M.K. (2018) ‘CD8 T Cells and mTOR: New Concepts and Targets for Systemic Lupus Erythematosus’, *The Lancet*, 391(10126), pp. 1126–1127. Available at: [https://doi.org/10.1016/S0140-6736\(18\)30544-0](https://doi.org/10.1016/S0140-6736(18)30544-0).
- Galicia-Garcia, U. *et al.* (2020) ‘Pathophysiology of Type 2 Diabetes Mellitus’, *International Journal of Molecular Sciences*, 21(17), pp. 1–34. Available at: <https://doi.org/10.3390/ijms21176275>.
- Giorgino, F. *et al.* (2021) ‘Management of Patients with Diabetes and Obesity in The COVID-19 Era: Experiences and Learnings from South and East Europe, The Middle East, and Africa’, *Diabetes Research and Clinical Practice*, 172. Available at: <https://doi.org/10.1016/j.diabres.2020.108617>.
- Gonga, L. *et al.* (2012) ‘Metformin Pathways: Pharmacokinetics and pharmacodynamics’, *Pharmacogenet Genomics*, 22(11), pp. 820–827. Available at: <https://doi.org/10.1097/FPC.0b013e3283559b22>.
- Goyal, R. and Jialal, I. (2022) ‘Diabetes Mellitus Type 2’, *StatPearls Publishing*, 1. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK513253/>.
- Groff, A. *et al.* (2021) ‘Gastrointestinal Manifestations of COVID-19: A Review of What We Know’, *Ochsner Journal*, 21(2), pp. 177–180. Available at: <https://doi.org/10.31486/toj.20.0086>.
- Harbuwono, D.S. *et al.* (2022) ‘Impact of Diabetes Mellitus on COVID-19 Clinical Symptoms and Mortality: Jakarta’s COVID-19 Epidemiological Registry’, *Primary Care Diabetes*, 16(1), pp. 65–68. Available at: <https://doi.org/10.1016/j.pcd.2021.11.002>.
- Hardianto, D. (2020) ‘Telaah Komprehensif Diabetes Melitus: Klasifikasi, Gejala, Diagnosis, Pencegahan, dan Pengobatan’, *Jurnal Bioteknologi & Biosains Indonesia (JBBI)*, 7(2), pp. 304–317. Available at: <https://doi.org/10.29122/jbbi.v7i2.4209>.
- Holly, J.M.P. *et al.* (2020) ‘Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle’, *Frontiers in Endocrinology*, 11. Available at: <https://doi.org/10.3389/fendo.2020.582870>.

- Ibrahim, S. *et al.* (2021) ‘Metformin and Covid-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit’, *Frontiers in Endocrinology*, 12(July), pp. 1–11. Available at: <https://doi.org/10.3389/fendo.2021.587801>.
- Inzucchi, S.E. (2023) ‘Management of Diabetes Mellitus in Hospitalized Patients’, *UpToDate* [Preprint]. Available at: <https://www.uptodate.com/contents/management-of-diabetes-mellitus-in-hospitalized-patients#H9> (Accessed: 30 March 2023).
- Jiang, N. *et al.* (2020) ‘Association of Metformin with Mortality or ARDS in Patients with COVID-19 and Type 2 Diabetes: A Retrospective Cohort Study’, *Diabetes Research and Clinical Practice*, 173, pp. 1–10. Available at: <https://doi.org/10.1016/j.diabres.2020.108619>.
- John, T.M., Jacob, C.N. and Kontoyiannis, D.P. (2021) ‘When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis’, *Journal of Fungi*, 7(4), p. 298. Available at: <https://doi.org/10.3390/jof7040298>.
- Joshi, T. *et al.* (2019) ‘Targeting AMPK Signaling Pathway by Natural Products For Treatment of Diabetes Mellitus and Its Complications’, *Journal of Cell Physiology*, 234, pp. 17212–17231. Available at: <https://doi.org/10.1002/jcp.28528>.
- Kamyshnyi, O. *et al.* (2021) ‘Metformin to Decrease COVID-19 Severity and Mortality: Molecular Mechanisms and Therapeutic Potential’, *Biomedicine and Pharmacotherapy*, 144, pp. 1–12. Available at: <https://doi.org/10.1016/j.biopha.2021.112230>.
- Kan, C. *et al.* (2021) ‘Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis’, *Frontiers in Endocrinology*. Frontiers Media S.A. Available at: <https://doi.org/10.3389/fendo.2021.708494>.
- Kausar, S. *et al.* (2021) ‘A Review: Mechanism of Action of Antiviral Drugs’, *International Journal of Immunopathology and Pharmacology*. SAGE Publications Inc. Available at: <https://doi.org/10.1177/20587384211002621>.

- KepMenKes RI (2020) *Keputusan Menteri Kesehatan Republik Indonesia No. HK.01.07/ MENKES/169/ 2020 Tentang Penetapan Rumah Sakit Rujukan Penanggulangan Penyakit Infeksi Emerging Tertentu.*
- Kristanti, W., Yulia, R. and Herawati, F. (2022) ‘Analysis of Antibiotic Use in COVID-19 Patients at a Hospital in Sidoarjo’, *Jurnal Farmasi dan Ilmu Kefarmasian Indonesia*, 9(2), pp. 200–208. Available at: <https://doi.org/10.20473/jfiki.v9i22022.200-208>.
- Kshanti, I.A. *et al.* (2020) ‘Clinical presentation and outcome of covid-19 infection in type 2 diabetes mellitus: A preliminary data from a tertiary hospital in jakarta during the early days of the pandemic’, *Bali Medical Journal*, 9(3), pp. 663–669. Available at: <https://doi.org/10.15562/bmj.v9i3.1969>.
- Lally, M.A. *et al.* (2021) ‘Metformin is Associated with Decreased 30-Day Mortality Among Nursing Home Residents Infected with SARS-CoV2’, *Journal of the American Medical Directors Association*, 22(1), pp. 193–198. Available at: <https://doi.org/10.1016/j.jamda.2020.10.031>.
- Li, J. *et al.* (2022) ‘Inpatient Use of Metformin and Acarbose is Associated with Reduced Mortality of COVID-19 Patients with Type 2 Diabetes Mellitus’, *Endocrinology, Diabetes and Metabolism*, 5(1). Available at: <https://doi.org/10.1002/edm2.301>.
- Lim, S. *et al.* (2021) ‘COVID-19 and Diabetes Mellitus: from Pathophysiology to Clinical Management’, *Nature Reviews Endocrinology*, 17, pp. 11–30. Available at: <https://doi.org/10.1038/s41574-020-00435-4>.
- Luo, P. *et al.* (2020) ‘Metformin Treatment was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis’, *American Journal of Tropical Medicine and Hygiene*, 103(1), pp. 69–72. Available at: <https://doi.org/10.4269/ajtmh.20-0375>.
- Mai, F., Pinto, R. Del and Ferri, C. (2020) ‘COVID-19 and Cardiovascular Diseases’, *Journal of Cardiology*, 76(5), pp. 453–458. Available at: <https://doi.org/10.1016/j.jjcc.2020.07.013>.
- Mirani, M. *et al.* (2020) ‘Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes with COVID-19 : A Case Series from an Academic Hospital in Lombardy, Italy’,

- Diabetes Care*, 43(12), pp. 3042–3049. Available at: <https://doi.org/https://doi.org/10.2337/dc20-1340>.
- Mueller, A.L., McNamara, M.S. and Sinclair, D.A. (2020) ‘Why Does COVID-19 Disproportionately Affect Older People?’, *Aging*, 12(10). Available at: <https://doi.org/10.18632/aging.103344>.
- Nakeshbandi, M. *et al.* (2020) ‘The Impact of Obesity on COVID-19 Complications: A Retrospective Cohort Study’, *International Journal of Obesity*, 44(9), pp. 1832–1837. Available at: <https://doi.org/10.1038/s41366-020-0648-x>.
- Nassar, M. *et al.* (2021) ‘Diabetes Mellitus and COVID-19: Review Article’, *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 15(6). Available at: <https://doi.org/10.1016/j.dsx.2021.102268>.
- Nguyen, N.N. *et al.* (2022) ‘Preadmission Use of Antidiabetic Medications and Mortality among Patients with COVID-19 Having Type 2 Diabetes: A Meta-Analysis’, *Metabolism: Clinical and Experimental*, 131. Available at: <https://doi.org/10.1016/j.metabol.2022.155196>.
- Ouchi, D. *et al.* (2022) ‘Antidiabetic Treatment and COVID-19 Outcomes: A Population-Based Cohort Study in Primary Health Care in Catalonia during the First Wave of the Pandemic’, *Primary Care Diabetes*, 16(6), pp. 753–759. Available at: <https://doi.org/10.1016/j.pcd.2022.10.001>.
- Pangribowo, S. (2020) *InfoDATIN Tetap Produktif, Cegah, dan Atasi Diabetes Melitus*. 1st edn. Edited by W. Widiyanti. Kementerian Kesehatan Republik Indonesia.
- Pemprov DKI Jakarta (2022) *Data Pemantauan COVID-19 DKI Jakarta*. Available at: <https://corona.jakarta.go.id/id/data-pemantauan>.
- Peng, M. *et al.* (2021) ‘Role of Hypertension on The Severity of COVID-19: A Review’, *Journal of Cardiovascular Pharmacology*, 78(5), pp. e648–e655. Available at: <https://doi.org/10.1097/FJC.0000000000001116>.
- PERKENI (2021) *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2021*. 1st edn. Edited by S.A. Soelistijo *et al.* PB PERKENI.
- Perrotta, F. *et al.* (2020) ‘COVID-19 and The Elderly: Insights into Pathogenesis and Clinical Decision-Making’, *Aging Clinical and Experimental Research*,

32(8), pp. 1599–1608. Available at: <https://doi.org/10.1007/s40520-020-01631-y>.

PUSDATIN (2020) *Situasi COVID-19*. 1st edn. Edited by W. Widiyanti.

Qing, L. *et al.* (2019) ‘Metformin Induces The M2 Macrophage Polarization to Accelerate The Wound Healing Via Regulating AMPK/mTOR/NLRP3 Inflammasome Singling Pathway’, *Am J Transl Res*, 11(2), pp. 655–668. Available at: [www.ajtr.org](http://www.ajtr.org).

Ranganathan, P., Aggarwal, R. and Pramesh, C. (2015) ‘Common Pitfalls in Statistical Analysis: Odds Versus Risk’, *Perspectives in Clinical Research*, 6(4), p. 222. Available at: <https://doi.org/10.4103/2229-3485.167092>.

Rebold, N. *et al.* (2022) ‘Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19’, *Infectious Diseases and Therapy*, 11(3), pp. 1281–1296. Available at: <https://doi.org/10.1007/s40121-022-00636-6>.

Rena, G., Hardie, D.G. and Pearson, E.R. (2017) ‘The Mechanisms of Action of Metformin’, *Diabetologia*, 60(9), pp. 1577–1585. Available at: <https://doi.org/10.1007/s00125-017-4342-z>.

Sahay, R.K. *et al.* (2020) ‘Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence’, *Cureus* [Preprint]. Available at: <https://doi.org/10.7759/cureus.10700>.

Salvatore, T. *et al.* (2020) ‘Metformin: A Potential Therapeutic Tool for Rheumatologists’, *Pharmaceuticals*, 13(9), pp. 1–16. Available at: <https://doi.org/10.3390/ph13090234>.

Samuel, S.M., Varghese, E. and Büsselberg, D. (2021) ‘Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role’, *Trends in Microbiology*. Elsevier Ltd, pp. 894–907. Available at: <https://doi.org/10.1016/j.tim.2021.03.004>.

Sanchez-Rangel, E. and Inzucchi, S.E. (2017) ‘Metformin: Clinical Use in Type 2 Diabetes’, *Diabetologia*, 60(9), pp. 1586–1593. Available at: <https://doi.org/10.1007/s00125-017-4336-x>.

- Saqib, U. *et al.* (2018) ‘Phytochemicals as Modulators of M1-M2 Macrophages in Inflammation’, *Oncotarget*, 9(25), pp. 17937–17950. Available at: [www.oncotarget.com](http://www.oncotarget.com).
- Satgas COVID-19 (2022) *Peta Sebaran COVID-19*. Available at: <https://covid19.go.id/peta-sebaran> (Accessed: 14 September 2022).
- Schwartz, S.S. *et al.* (2016) ‘The Time is Right for a New Classification System for Diabetes: Rationale and Implications of The  $\beta$ -Cell-Centric Classification Schema’, *Diabetes Care*, 39(2), pp. 179–186. Available at: <https://doi.org/10.2337/dc15-1585>.
- Shyr, Z.A. *et al.* (2020) ‘Drug Discovery Strategies for SARS-CoV-2’, *Journal of Pharmacology and Experimental Therapeutics*, 375(1), pp. 127–138. Available at: <https://doi.org/10.1124/JPET.120.000123>.
- Singh, D., Mathioudakis, A.G. and Higham, A. (2022) ‘Chronic Obstructive Pulmonary Disease and COVID-19: Interrelationships’, *Current Opinion in Pulmonary Medicine*, 28(2), pp. 76–83. Available at: <https://doi.org/10.1097/MCP.0000000000000834>.
- Singh, S. and Bajorek, B. (2014) ‘Defining “Elderly” in Clinical Practice Guidelines for Pharmacotherapy’, *Pharmacy Practice*, 12(4), p. 489. Available at: <https://doi.org/10.4321/s1886-36552014000400007>.
- Solis-Herrera, C. *et al.* (2018) *Classification of Diabetes Mellitus, Endotext*. Edited by K. Feingold, B. Anawalt, and A. Boyce. Endotext.
- Sutriyawan, A. (2021) *Metodologi Penelitian Kedokteran dan Kesehatan Dilengkapi Tuntunan Membuat Proposal Penelitian*. 1st edn. Edited by N.F. Atif. Bandung: PT Refika Aditama.
- Tsivgoulis, G. *et al.* (2020) ‘COVID-19 and Cerebrovascular Diseases: A Comprehensive Overview’, *Therapeutic Advances in Neurological Disorders*, 13, pp. 1–18. Available at: <https://doi.org/10.1177/1756286420978004>.
- Ursini, F. *et al.* (2018) ‘Metformin and autoimmunity: A “new deal” of an old drug’, *Frontiers in Immunology*, 9(JUN), pp. 1–12. Available at: <https://doi.org/10.3389/fimmu.2018.01236>.



- Varga, Z. *et al.* (2020) ‘Endothelial Cell Infection and Endotheliitis in COVID-19’, *The Lancet*, 395(10234), pp. 1417–1418. Available at: [https://doi.org/10.1016/S0140-6736\(20\)30937-5](https://doi.org/10.1016/S0140-6736(20)30937-5).
- Wang, D. *et al.* (2020) ‘Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China’, *JAMA - Journal of the American Medical Association*, 323(11), pp. 1061–1069. Available at: <https://doi.org/10.1001/jama.2020.1585>.
- Wang, L. *et al.* (2021) ‘An Observational Cohort Study of Bacterial Co-Infection and Implications for Empirical Antibiotic Therapy in Patients Presenting with COVID-19 to Hospitals in North West London’, *Journal of Antimicrobial Chemotherapy*, 76(3), pp. 796–803. Available at: <https://doi.org/10.1093/jac/dkaa475>.
- Wang, Y. *et al.* (2020) ‘Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19’, *American Journal of Respiratory and Critical Care Medicine*. American Thoracic Society, pp. 1430–1434. Available at: <https://doi.org/10.1164/rccm.202003-0736LE>.
- Wolff, D. *et al.* (2021) ‘Risk Factors for Covid-19 Severity and Fatality: a Structured Literature Review’, *Infection*, 49(1), pp. 15–28. Available at: <https://doi.org/10.1007/s15010-020-01509-1>.
- Woolcott, O.O. and Castilla-Bancayán, J.P. (2021) ‘The Effect of Age on The Association between Diabetes and Mortality in Adult Patients with COVID-19 in Mexico’, *Scientific Reports*, 11(1). Available at: <https://doi.org/10.1038/s41598-021-88014-z>.
- World Health Organization (2021) ‘COVID-19 Disease in Children and Adolescents’, *Scientific brief*, (September), pp. 1–10. Available at: [https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci\\_Brief-Children\\_and\\_adolescents-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Children_and_adolescents-2021.1).
- Wulandari, E.W., Rotnoatmodjo, S. and Salama, N. (2022) ‘Diabetes Mellitus and Mortality among COVID-19 Patients in Jakarta, March-August 2020’, *Jurnal Kesehatan Masyarakat Nasional*, 17(2), pp. 157–164. Available at: <https://doi.org/10.21109/kesmas.v17i2.5815>.

- Yang, W. *et al.* (2021) ‘The Effect of Metformin on Mortality and Severity in COVID-19 Patients with Diabetes Mellitus’, *Diabetes Research and Clinical Practice*, 178. Available at: <https://doi.org/10.1016/j.diabres.2021.108977>.
- Ye, C. *et al.* (2020) ‘Impact of Comorbidities on Patients with COVID-19: A Large Retrospective Study in Zhejiang, China’, *Journal of Medical Virology*, 92(11), pp. 2821–2829. Available at: <https://doi.org/10.1002/jmv.26183>.
- Yitao, Z. *et al.* (2021) ‘Predictors of Clinical Deterioration in Non-Severe Patients with COVID-19: a Retrospective Cohort Study’, *Current Medical Research and Opinion*, 37(3), pp. 385–391. Available at: <https://doi.org/https://doi.org/10.1080/03007995.2021.1876005>.
- Zhang, J. *et al.* (2020) ‘Impaired Fasting Glucose and Diabetes Are Related to Higher Risks of Complications and Mortality Among Patients with Coronavirus Disease 2019’, *Frontiers in Endocrinology*, 11, p. 525. Available at: <https://doi.org/10.3389/fendo.2020.00525>.
- Zhang, Q. *et al.* (2020) ‘Clinical Analysis of Risk Factors for Severe COVID-19 Patients with Type 2 Diabetes’, *Journal of Diabetes and its Complications*, 34(10). Available at: <https://doi.org/10.1016/j.jdiacomp.2020.107666>.